Long-term treatment in rheumatoid arthritis: do biological and targeted-synthetic DMARDs increase the risk of malignancy?
- PMID: 34648000
- DOI: 10.1093/rheumatology/keab750
Long-term treatment in rheumatoid arthritis: do biological and targeted-synthetic DMARDs increase the risk of malignancy?
Comment on
-
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.Rheumatology (Oxford). 2022 May 5;61(5):1810-1818. doi: 10.1093/rheumatology/keab570. Rheumatology (Oxford). 2022. PMID: 34324640 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
